BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BioNTech SE (BNTX) Slides on Vaccine Revenue Miss But Consensus Was 'Too High'
August 8, 2022 3:32 PM EDTBioNTech SE (NASDAQ: BNTX) shares tumbled more than 9% Monday after reporting second-quarter earnings before the open.
The drugmaker posted second-quarter earnings of 6.45 per share on revenue of 3.2 billion. Earnings and revenue fell from the second quarter of 2021, where it reported a profit of 10.77 per share on revenue of $5.3 billion.
"With our strong performance year to date, we believe to be well on track to achieve our previous financial guidance for the ongoing financial year,"... More
